• Negotiated the BD contract for entire MSD portfolio; • Introduced new business model with all portfolio outsourced to distributor (Berlin-Chemie); • Achieved 35% volume growth achieved while developing the cooperation model (first 9 months) with Berlin-Chemie; • Initiated and executed change of MSD regulatory procedures to better serve the markets and the partner; • Implemented divestiture/transfer of MSD products to Aspen (Ovestin, Sustanon) and Bayer (Claritine, Aerius, Freederm); • Negotiated key terms for the outsource contract in Ukraine (Pro-Pharma).

• Full P&L responsibility • Decreased operating expenses by 40% by restructuring country organizations (cost optimization after the merger); • Changed distribution model in Georgia; • Successfully pushed for addition of Celestina (distributor from Lithuania) as the distributor in Belarus; • Implemented/managed third party promotion contracts (Belarus and Georgia); • Managed bad debt recovery in Azerbaijan; • Shifted pricing strategy to minimize parallel import (Georgia, Azerbaijan); • Achieved 20% sales growth in 2013 (2nd year after restructuring);

• Established new team to support S&M (SFE Manger, Trainer, Marketing Manager); • Introduced new country head in Kazakhstan; • Initiated/executed patent extension for INVANZ in Belarus; • Prepared Business Case for Ukraine as the top emerging market (team effort);

• EMEND (aprepitant): prepared reimbursement application in Poland; corrected price for re-submissions in Croatia & Czech Republic; initiated and secured budget for market research leading to change of promo strategy in Israel and South Africa; • TEMODAL (temozolomide): initiated product re-launch in Egypt; organized 2 international events to share best practices and prolong brand loyalty; saved Russian $ 5MM tender from failure; • Secured budget and coordinated development of CINV and melanoma treatment guidelines in Russia

Medical Faculty, Medical doctor